FDA Approves Stiolto® Respimat® Supplemental New Drug Application (sNDA) to Add Data on COPD Exacerbation Reduction

Press/Media: Press / Media

PeriodOct 11 2018 → Oct 12 2018

Media coverage

3

Media coverage

  • TitleFDA Approves Stiolto® Respimat® Supplemental New Drug Application (sNDA) to Add Data on COPD Exacerbation Reduction
    Media name/outletPlus Company Updates (PCU)
    CountryUnited States
    Date10/12/18
    PersonsAntonio R Anzueto
  • TitleFDA Approves Stiolto® Respimat® Supplemental New Drug Application (sNDA) to Add Data on COPD Exacerbation Reduction
    Media name/outletBioSpace
    CountryUnited States
    Date10/11/18
    PersonsAntonio R Anzueto
  • TitleFDA Approves Stiolto® Respimat® Supplemental New Drug Application (sNDA) to Add Data on COPD Exacerbation Reduction
    Media name/outletPharmiWeb
    CountryUnited Kingdom
    Date10/11/18
    PersonsAntonio R Anzueto